Key result
Simvastatin therapy significantly reduced blood lipid levels and urinary 11-dehydro-TXB2 excretion in patients with type IIa hypercholesterolemia (P<0.001).
Why the study?
Does simvastatin reduce TXA2 biosynthesis and improve platelet function in patients with type IIa hypercholesterolemia?
Population
24 patients with type IIa hypercholesterolemia
Comparison
Simvastatin 20 mg/d for 3 months vs Placebo for 3 months
Design
RCT, randomized, double-blind
Follow-up
3 months
Authors
Loading...
Simvastatin may enhance antithrombotic strategies alongside lipids in hypercholesterolemia; extends RCT evidence for statin pleiotropy on platelets.
RCT (n=24)
Double-blind
randomized
Does simvastatin reduce TXA2 biosynthesis and improve platelet function in patients with type IIa hypercholesterolemia?
p-value: p=<0.001
Simvastatin significantly reduces thromboxane A2 biosynthesis and platelet aggregation in patients with type IIa hypercholesterolemia, with effects correlating strongly with lipid reduction.
Notarbartoló et al. (1995) conducted an RCT in type IIa hypercholesterolemia (n=24). simvastatin vs. placebo was evaluated on urinary excretion of 11-dehydro-TXB2 and blood lipid levels (p=<0.001). Simvastatin therapy significantly reduced blood lipid levels and urinary 11-dehydro-TXB2 excretion in patients with type IIa hypercholesterolemia (P<0.001).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: